NuGen Medical Devices Inc.
NGMD.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 46.79% | 131.25% | 139.52% | 351.80% | -35.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.79% | 131.25% | 139.52% | 351.80% | -35.12% |
| Cost of Revenue | 52.38% | 133.33% | 73.41% | 525.24% | -42.47% |
| Gross Profit | 43.28% | 130.77% | 254.75% | 250.46% | -28.72% |
| SG&A Expenses | 59.54% | -47.56% | -56.85% | 10.56% | -73.22% |
| Depreciation & Amortization | 1.37% | -14.08% | 0.71% | -14.35% | -12.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.93% | -41.30% | -47.25% | 18.44% | -67.88% |
| Operating Income | -45.91% | 46.83% | 61.60% | -0.04% | 68.24% |
| Income Before Tax | -141.63% | 180.73% | 119.31% | -27.04% | 60.89% |
| Income Tax Expenses | -- | -- | -114.97% | 1,480.00% | -- |
| Earnings from Continuing Operations | -142.06% | 180.53% | 119.26% | -27.46% | 61.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -142.06% | 180.53% | 119.26% | -27.46% | 61.01% |
| EBIT | -45.91% | 46.83% | 61.60% | -0.04% | 68.24% |
| EBITDA | -59.83% | 51.84% | 67.50% | -1.38% | 73.10% |
| EPS Basic | -131.25% | 172.73% | 117.89% | -8.70% | 70.64% |
| Normalized Basic EPS | -119.05% | 173.17% | 76.27% | -3.33% | 68.66% |
| EPS Diluted | -131.25% | 172.73% | 117.89% | -8.70% | 70.64% |
| Normalized Diluted EPS | -119.05% | 173.17% | 76.27% | -3.33% | 68.66% |
| Average Basic Shares Outstanding | 5.17% | 10.48% | 10.21% | 17.73% | 31.52% |
| Average Diluted Shares Outstanding | 5.17% | 10.48% | 10.21% | 17.73% | 31.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |